WRAL Tech Wire

Salix rectal inflammation drug shows positive clinical trial results

Salix Pharmaceuticals' topical foam to treat rectal inflammation could be filed for approval with the Food and Drug Administration by the end of September.

Prescription growth lifts Salix's 1Q sales

First quarter sales of Salix Pharmaceuticals' top drug, Xifaxan, increased 18 percent year over year. Read more about the company's performance.

 FDA makes Salix wait on constipation drug; company says no new trials needed

The FDA said it needed more data to approve expanded use of Salix Pharmaceutical's constipation drug Relistor. Read why Salix thinks it has enough information.

 Salix CEO gears for federal probe that could go on for 'quite some time'

Carolyn Logan, chief executive officer at Raleigh-based Salix pharmaceuticals, and the company are gearing up for what could be a lengthy federal investigation into its marketing practices.

 Feds subpoena Salix, ask about drug promotion practices

Federal prosecutors have questions about how Salix Pharmaceuticals (NASDAQ:SLXP) sells and promotes its drugs, including its top-selling product Xifaxan.

 Drug approval sends Salix shares up nearly 5%

Shares in Salix Pharmaceuticals rose nearly 5 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

 FDA approves new Salix drug to treat AIDS-related diarrhea

Shares in Salix Pharmaceuticals rose more than 3 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

 Earnings: Salix; PowerSecure; Pozen; BioCryst

Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

 Raleigh drug firm Salix sponsors documentary on liver disease

Salix Pharmaceuticals and the American Liver Foundation back a new documentary about hepatic encephalopathy, or HE, which was directed by Academy Award winner Cynthia Wade.

Salix backs "HE" documentary

 FDA again delays Salix gastrointestinal drug

The FDA has again delayed an approval decision for a new diarrhea drug from Salix Pharmaceuticals.

 Salix pays $10M upfront for possible treatment of Crohn's Disease

The Raleigh-based pharmaceutical firm licenses rights to an extended release version of the drug Rifaximin that targets gastrointestinal and respiratory ailments.

 Earnings: Salix, Cempra, Targacept, Cornerstone

Four North Carolina-based life science firms report an overall mixed bag of results, but Raleigh-based Salix reports huge jump in sales.

 Salix delays big hiring plans after FDA rejects drug

Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8.

 In the news: Quintiles, Salix, Furiex, AAD

Inside the Bulldog Blog: Quintiles lands drug promotion deal; Salix seeks FDA meeting about drug response; Furiex resubmits diabetes drug; Advanced Animal Diagnostics adds two execs.

 Salix revenue rises 62% in first quarter, beats Street

Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.

 FDA delays decision on Salix drug to treat HIV-related diarrhea

Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.

 FDA oushes back review for Salix constipation treatment

An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.

 Raleigh-based Salix Pharmaceuticals to raise $600M

Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.

 How long before Salix Pharmaceuticals hits $1B?

After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.

 In the news: Visilink's LED wireless; MercuryGate grows; Salix drug trial; Furiex cuts losses; iContact donations; Software Toolbox update

Local tech briefs: Cary-based Visilink unveils LED-based wireless; Cary firm MercuryGate expands to Asia; Salix launches new drug trial; Furiex cuts its losses; iContact donates $200,000; Charlotte firm updates automation software.